Histalim – in situ hybridization and histology

Histalim is a service provider company in histology, immunohistochemistry (IHC), in situ hybridization (ISH), and image analysis. Its laboratory located in Montpellier was founded in 2005 while its sale offices in Berlin were opened in 2014. This positioning shows its willingness to meet the increasing demand to design, develop, and validate protocols based on standard and/or innovative techniques.

Histalim – in situ hybridization and histology

HISTALIM

Continue reading

Juno Therapeutics – next generation CAR technology

Juno Therapeutics is a biopharma company developing novel cellular immunotherapies based on two distinct and complementary platforms: T Cell Receptors (TCRs) and Chimeric Antigen Receptors (CARs) technologies.

Juno Therapeutics – next generation CAR technology

Juno Therapeutics Continue reading

Adaptimmune – engineered, increased affinity T cell receptors

Adaptimmune is focused on T cells to target and destroy cancer by using engineered, increased affinity T cell receptors (TCRs) as a means of strengthening natural patient T cell responses.

Adaptimmune – engineered, increased affinity T cell receptors

adaptimmune Continue reading

Immunocore – T cell receptor-based drugs

Immunocore is a clinical-stage biotech company focused on the development of novel T cell receptor-based drugs to treat cancers and viral diseases. Immunocore is the world-leader in engineering T Cell Receptors (TCRs) and link them to an antibody fragment (scFv). Its first product candidate, IMCgp100, entered clinical trials in patients with metastatic melanoma.

Immunocore – T cell receptor-based drugs

Immunocore

Continue reading